Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Harvard Business School
Chinese Patent Office
Daiichi Sankyo
Covington
Cipla
Teva
Farmers Insurance
Novartis
Medtronic

Generated: October 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,582,728

« Back to Dashboard

Which drugs does patent 6,582,728 protect, and when does it expire?


Patent 6,582,728 protects EXUBERA and is included in one NDA.

This patent has two hundred and twenty-five patent family members in forty-four countries.

Summary for Patent: 6,582,728

Title: Spray drying of macromolecules to produce inhaleable dry powders
Abstract:According to the subject invention, dispersible dry powder pharmaceutical-based compositions are provided, including methods for their manufacture and dry powder dispersion devices. A dispersible dry powder pharmaceutical-based composition is one having a moisture content of less than about 10% by weight (%w) water, usually below about 5%w and preferably less than about 3%w; a particle size of about 1.0-5.0 .mu.m mass median diameter (MMD), usually 1.0-4.0 .mu.m MMD, and preferably 1.0-3.0 .mu.m MMD; a delivered dose of about >30%, usually >40%, preferably >50%, and most preferred >60%; and an aerosol particle size distribution of about 1.0-5.0 .mu.m mass median aerodynamic diameter (MMAD), usually 1.5-4.5 .mu.m MMAD, and preferably 1.5-4.0 MMAD. Such composition are of pharmaceutical grade purity.
Inventor(s): Platz; Robert M. (Half Moon Bay, CA), Patton; John S. (San Carlos, CA), Foster; Linda (Sunnyvale, CA), Eljamal; Mohammed (San Jose, CA)
Assignee: Inhale Therapeutic Systems, Inc. (San Carlos, CA)
Application Number:08/423,515
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pfizer
EXUBERA
insulin recombinant human
POWDER;INHALATION021868-001Jan 27, 2006DISCNNoNo► Subscribe► SubscribeY
Pfizer
EXUBERA
insulin recombinant human
POWDER;INHALATION021868-002Jan 27, 2006DISCNNoNo► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,582,728

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,589,560 Stable glassy state powder formulations► Subscribe
5,780,014 Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin► Subscribe
6,681,767 Method and device for delivering aerosolized medicaments► Subscribe
6,165,463 Dispersible antibody compositions and methods for their preparation and use► Subscribe
6,123,936 Methods and compositions for the dry powder formulation of interferons► Subscribe
6,080,721 Pulmonary delivery of active fragments of parathyroid hormone► Subscribe
6,258,341 Stable glassy state powder formulations► Subscribe
5,458,135 Method and device for delivering aerosolized medicaments► Subscribe
7,300,919Pulmonary delivery of active fragments of parathyroid hormone► Subscribe
5,993,783 Method and apparatus for pulmonary administration of dry powder .alpha.1-antitrypsin► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,582,728

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO)9801369► Subscribe
African Regional IP Organization (ARIPO)987► Subscribe
Argentina013854► Subscribe
Argentina042921► Subscribe
Austria189124► Subscribe
Austria220327► Subscribe
Austria245969► Subscribe
Austria260688► Subscribe
Austria261742► Subscribe
Austria264096► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Harvard Business School
Merck
Boehringer Ingelheim
Deloitte
Chubb
Mallinckrodt
Cerilliant
Farmers Insurance
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot